...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Just back from IR,...
8
Oct 25, 2019 06:48PM
1
Oct 25, 2019 08:34PM
5
Oct 25, 2019 09:18PM
7
Oct 25, 2019 11:03PM
12
Oct 25, 2019 11:20PM
6
Oct 26, 2019 01:42AM
3
Oct 26, 2019 01:45AM
5
Oct 26, 2019 05:39AM
4
Oct 26, 2019 05:51AM
7
Oct 26, 2019 09:11AM
2
Oct 26, 2019 09:55AM
6
Oct 26, 2019 11:07AM
4
Oct 26, 2019 11:25AM
3
Oct 26, 2019 12:26PM
4
Oct 26, 2019 12:34PM
4
Oct 26, 2019 01:05PM
2
Oct 26, 2019 02:01PM
3
Oct 26, 2019 02:11PM
9
Oct 26, 2019 05:33PM
6
Oct 26, 2019 07:21PM
3
Oct 26, 2019 07:29PM
12
Oct 27, 2019 09:47AM

We have to keep in mind they have to be really careful. They know we want to dissect their every word and will try to interpret everything they say. That ‘s the problem, because they are forbidden to give too much away at this stage.  If they are careless, they could cause big problems for themselves. Even a qualitative comment about forthcoming results being « exciting » or « disappointing » , for example, could be too much. So, much of the vagueness and ambiguity is probably intentional.

In my view, the company has done a pretty good job over the years. It’s been a long hard slog and they have kept at it, conducted the trials well, and now  (let’s hope!!) may be on the verge of a medical breakthrough. 

1
Oct 27, 2019 11:00AM
3
Oct 27, 2019 11:14AM
2
Oct 27, 2019 11:15AM
1
Oct 27, 2019 11:28AM
3
Oct 27, 2019 02:40PM
2
Oct 27, 2019 03:03PM
2
Oct 27, 2019 03:43PM
3
Oct 27, 2019 03:48PM
2
Oct 27, 2019 05:10PM
4
Oct 27, 2019 06:39PM
1
Oct 27, 2019 10:00PM
2
Oct 28, 2019 05:29PM
1
Oct 28, 2019 05:43PM
7
Oct 28, 2019 08:51PM
5
Oct 29, 2019 08:32AM
3
Oct 29, 2019 08:56AM
1
Oct 29, 2019 09:28AM
2
Oct 29, 2019 10:05AM
3
Oct 29, 2019 10:34AM
2
Oct 29, 2019 10:54AM
2
Oct 29, 2019 11:08AM
4
Oct 29, 2019 11:50AM
2
Oct 29, 2019 12:08PM
5
Oct 29, 2019 12:09PM
4
Oct 29, 2019 02:49PM
5
Oct 29, 2019 05:58PM
4
Oct 29, 2019 07:11PM
3
Oct 29, 2019 07:29PM
3
Oct 29, 2019 07:48PM
2
Oct 31, 2019 03:07PM
Share
New Message
Please login to post a reply